Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/23094| Title: | Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. | Austin Authors: | Seymour, John F;Marcus, Robert;Davies, Andrew;Gallop-Evans, Eve;Grigg, Andrew P ;Haynes, Andrew;Herold, Michael;Illmer, Thomas;Nilsson-Ehle, Herman;Sökler, Martin;Dünzinger, Ulrich;Nielsen, Tina;Launonen, Aino;Hiddemann, Wolfgang | Affiliation: | Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, Australia Kings College Hospital, London, UK F. Hoffmann-La Roche Ltd., Basel, Switzerland Austin Health, Heidelberg, Victoria, Australia Cancer Research UK Centre, University of Southampton, Southampton, UK Velindre Cancer Centre, Cardiff, UK Nottingham University Hospitals NHS Trust, Nottingham, UK HELIOS-Klinikum Erfurt, Germany BAG Freiberg-Richter, Jacobasch, Illmer and Wolf, Dresden, Germany Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden Eberhard-Karls-University Tübingen, Tübingen, Germany Roche Pharma AG, Grenzach-Wyhlen, Germany Department of Medicine III, Ludwig-Maximilians-University, München, Germany |
Issue Date: | May-2020 | Publication information: | Haematologica 2020; 105(5): 1465 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/23094 | DOI: | 10.3324/haematol.2020.246991 | Journal: | Haematologica | PubMed URL: | 32358081 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.